Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jazz Pharmaceuticals Plc on January 18, 2012. The report discloses the departure of a senior officer and the terms of a separation agreement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
Carol A. Gamble resigned as Senior Vice President, General Counsel, and Corporate Secretary, effective March 12, 2012. She will transition to a consultant role until July 12, 2012.
Guidance, Outlook, and Management Commentary
Management has entered into a Separation Agreement with Ms. Gamble. Key terms include:
- Consulting Compensation: $200 per hour for services during the transition period.
- Equity: Existing stock options will continue to vest during the consulting period.
- Lump Sum Payment: A single payment equal to ten months of her current base salary (less deductions) in exchange for a general release of claims.
- Benefits: Company will pay COBRA premiums for health insurance until the earlier of coverage under a new plan or December 31, 2012.
- Bonus: Ms. Gamble remains eligible for her full 2011 annual bonus.
Investor Verification Checklist
- Verify the exact base salary used to calculate the ten-month lump sum payment.
- Review the full Separation Agreement filed as an exhibit to the Form 10-K for the fiscal year ended December 31, 2011.
- Confirm the status of Ms. Gamble's stock options and vesting schedule.
- Monitor for the appointment of a replacement General Counsel and Corporate Secretary.